MEM 1003

Drug Profile

MEM 1003

Alternative Names: BAY Z 4406

Latest Information Update: 22 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Memory Pharmaceuticals
  • Class Antidementias; Dihydropyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Bipolar disorders; Mild cognitive impairment; Vascular dementia

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in cognitive decline and Alzheimer's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 18 Oct 2007 Final results from a phase IIa clinical trial in patients with Alzheimer's disease added to the adverse events and Alzheimier's Disease therapeutic trials sections
  • 11 Apr 2007 Memory Pharmaceuticals completes enrolment in its phase IIa trial for Alzheimer's Disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top